beta

ALVO

Alvotech

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a

Market Cap: 4.25 Billion

Primary Exchange: NASDAQ

Website:

Shares Outstanding: 266 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.5095776519515365

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in Biotechnology

Ethical Flags

Longest drawdown: 240 trading days

From: 2023-03-02 To: 2024-01-04

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud